Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes-cardiovascular and renal benefits in patients with chronic kidney disease.

Milder TY, Stocker SL, Samocha-Bonet D, Day RO, Greenfield JR.

Eur J Clin Pharmacol. 2019 Aug 3. doi: 10.1007/s00228-019-02732-y. [Epub ahead of print] Review.

PMID:
31377891
2.

Education to improve vancomycin use - The perspectives of educators and education recipients.

Van Dort BA, Baysari MT, Carland JE, Stocker SL, Braithwaite HE, Fernon AR, Day RO.

Intern Med J. 2019 Jun 18. doi: 10.1111/imj.14408. [Epub ahead of print]

PMID:
31211885
3.

Improving adherence to urate-lowering therapy in people living with gout.

Coleshill MJ, Aung E, Nguyen AD, Stocker SL, Baysari MT, Kamel B, Schulz M, McLachlan AJ, Day RO.

Int J Rheum Dis. 2019 Apr;22(4):542-544. doi: 10.1111/1756-185X.13566. No abstract available.

PMID:
30985997
4.

Towards precision dosing of vancomycin: a systematic evaluation of pharmacometric models for Bayesian forecasting.

Broeker A, Nardecchia M, Klinker KP, Derendorf H, Day RO, Marriott DJ, Carland JE, Stocker SL, Wicha SG.

Clin Microbiol Infect. 2019 Mar 11. pii: S1198-743X(19)30097-7. doi: 10.1016/j.cmi.2019.02.029. [Epub ahead of print]

PMID:
30872102
5.

Combination Therapy with an SGLT2 Inhibitor as Initial Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis.

Milder TY, Stocker SL, Abdel Shaheed C, McGrath-Cadell L, Samocha-Bonet D, Greenfield JR, Day RO.

J Clin Med. 2019 Jan 4;8(1). pii: E45. doi: 10.3390/jcm8010045. Review.

6.

Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance.

Zamek-Gliszczynski MJ, Taub ME, Chothe PP, Chu X, Giacomini KM, Kim RB, Ray AS, Stocker SL, Unadkat JD, Wittwer MB, Xia C, Yee SW, Zhang L, Zhang Y; International Transporter Consortium.

Clin Pharmacol Ther. 2018 Nov;104(5):890-899. doi: 10.1002/cpt.1112. Epub 2018 Aug 8. Review.

PMID:
30091177
7.

Clinical Pharmacokinetics in Kidney Disease: Application to Rational Design of Dosing Regimens.

Roberts DM, Sevastos J, Carland JE, Stocker SL, Lea-Henry TN.

Clin J Am Soc Nephrol. 2018 Aug 7;13(8):1254-1263. doi: 10.2215/CJN.05150418. Epub 2018 Jul 24.

8.

Clinical Pharmacokinetics in Kidney Disease: Fundamental Principles.

Lea-Henry TN, Carland JE, Stocker SL, Sevastos J, Roberts DM.

Clin J Am Soc Nephrol. 2018 Jul 6;13(7):1085-1095. doi: 10.2215/CJN.00340118. Epub 2018 Jun 22.

9.

Predicting Response or Non-response to Urate-Lowering Therapy in Patients with Gout.

Graham GG, Stocker SL, Kannangara DRW, Day RO.

Curr Rheumatol Rep. 2018 Jun 21;20(8):47. doi: 10.1007/s11926-018-0760-2. Review.

PMID:
29931553
10.

Individualising the dose of allopurinol in patients with gout.

Kannangara DRW, Graham GG, Wright DFB, Stocker SL, Portek I, Pile KD, Barclay ML, Williams KM, Stamp LK, Day RO.

Br J Clin Pharmacol. 2017 Sep;83(9):2015-2026. doi: 10.1111/bcp.13307. Epub 2017 May 28.

11.

Characterization of ADME gene variation in 21 populations by exome sequencing.

Hovelson DH, Xue Z, Zawistowski M, Ehm MG, Harris EC, Stocker SL, Gross AS, Jang IJ, Ieiri I, Lee JE, Cardon LR, Chissoe SL, Abecasis G, Nelson MR.

Pharmacogenet Genomics. 2017 Mar;27(3):89-100. doi: 10.1097/FPC.0000000000000260.

12.

Allopurinol: insights from studies of dose-response relationships.

Day RO, Kannangara DR, Stocker SL, Carland JE, Williams KM, Graham GG.

Expert Opin Drug Metab Toxicol. 2017 Apr;13(4):449-462. doi: 10.1080/17425255.2017.1269745. Epub 2016 Dec 20. Review.

PMID:
27927043
13.

Pharmacokinetics of Metformin in Patients Receiving Regular Hemodiafiltration.

Smith FC, Kumar SS, Furlong TJ, Gangaram SV, Greenfield JR, Stocker SL, Graham GG, Williams KM, Day RO.

Am J Kidney Dis. 2016 Dec;68(6):990-992. doi: 10.1053/j.ajkd.2016.08.017. Epub 2016 Oct 15. No abstract available.

PMID:
27751611
14.

Pharmacometabolomic Assessment of Metformin in Non-diabetic, African Americans.

Rotroff DM, Oki NO, Liang X, Yee SW, Stocker SL, Corum DG, Meisner M, Fiehn O, Motsinger-Reif AA, Giacomini KM, Kaddurah-Daouk R.

Front Pharmacol. 2016 Jun 14;7:135. doi: 10.3389/fphar.2016.00135. eCollection 2016.

15.

The Effect of Famotidine, a MATE1-Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin.

Hibma JE, Zur AA, Castro RA, Wittwer MB, Keizer RJ, Yee SW, Goswami S, Stocker SL, Zhang X, Huang Y, Brett CM, Savic RM, Giacomini KM.

Clin Pharmacokinet. 2016 Jun;55(6):711-21. doi: 10.1007/s40262-015-0346-3.

16.

The Effect of Nizatidine, a MATE2K Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin in Healthy Volunteers.

Morrissey KM, Stocker SL, Chen EC, Castro RA, Brett CM, Giacomini KM.

Clin Pharmacokinet. 2016 Apr;55(4):495-506. doi: 10.1007/s40262-015-0332-9.

17.

Targeted disruption of organic cation transporter 3 attenuates the pharmacologic response to metformin.

Chen EC, Liang X, Yee SW, Geier EG, Stocker SL, Chen L, Giacomini KM.

Mol Pharmacol. 2015 Jul;88(1):75-83. doi: 10.1124/mol.114.096776. Epub 2015 Apr 28.

18.

Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin.

Chung WH, Chang WC, Stocker SL, Juo CG, Graham GG, Lee MH, Williams KM, Tian YC, Juan KC, Jan Wu YJ, Yang CH, Chang CJ, Lin YJ, Day RO, Hung SI.

Ann Rheum Dis. 2015 Dec;74(12):2157-64. doi: 10.1136/annrheumdis-2014-205577. Epub 2014 Aug 12.

PMID:
25115449
19.

Reduced renal clearance of cefotaxime in asians with a low-frequency polymorphism of OAT3 (SLC22A8).

Yee SW, Nguyen AN, Brown C, Savic RM, Zhang Y, Castro RA, Cropp CD, Choi JH, Singh D, Tahara H, Stocker SL, Huang Y, Brett CM, Giacomini KM.

J Pharm Sci. 2013 Sep;102(9):3451-7. doi: 10.1002/jps.23581. Epub 2013 May 6.

20.

Understanding the dose-response relationship of allopurinol: predicting the optimal dosage.

Graham GG, Kannangara DR, Stocker SL, Portek I, Pile KD, Indraratna PL, Datta I, Williams KM, Day RO.

Br J Clin Pharmacol. 2013 Dec;76(6):932-8. doi: 10.1111/bcp.12126.

21.

HLA-B*5801 should be used to screen for risk of Stevens-Johnson syndrome in family members of Han Chinese patients commencing allopurinol therapy.

Lee MH, Stocker SL, Williams KM, Day RO.

J Rheumatol. 2013 Jan;40(1):96-7. doi: 10.3899/jrheum.120803. No abstract available.

PMID:
23280169
22.

Gene expression profiling of transporters in the solute carrier and ATP-binding cassette superfamilies in human eye substructures.

Dahlin A, Geier E, Stocker SL, Cropp CD, Grigorenko E, Bloomer M, Siegenthaler J, Xu L, Basile AS, Tang-Liu DD, Giacomini KM.

Mol Pharm. 2013 Feb 4;10(2):650-63. doi: 10.1021/mp300429e. Epub 2013 Jan 24.

23.

The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin.

Stocker SL, Morrissey KM, Yee SW, Castro RA, Xu L, Dahlin A, Ramirez AH, Roden DM, Wilke RA, McCarty CA, Davis RL, Brett CM, Giacomini KM.

Clin Pharmacol Ther. 2013 Feb;93(2):186-94. doi: 10.1038/clpt.2012.210. Epub 2012 Oct 17.

24.

Renal transporters in drug development.

Morrissey KM, Stocker SL, Wittwer MB, Xu L, Giacomini KM.

Annu Rev Pharmacol Toxicol. 2013;53:503-29. doi: 10.1146/annurev-pharmtox-011112-140317. Epub 2012 Nov 8. Review.

PMID:
23140242
25.

Fractional clearance of urate: validation of measurement in spot-urine samples in healthy subjects and gouty patients.

Kannangara DR, Ramasamy SN, Indraratna PL, Stocker SL, Graham GG, Jones G, Portek I, Williams KM, Day RO.

Arthritis Res Ther. 2012 Aug 17;14(4):R189. doi: 10.1186/ar4020.

26.

The pharmacokinetics of oxypurinol in people with gout.

Stocker SL, McLachlan AJ, Savic RM, Kirkpatrick CM, Graham GG, Williams KM, Day RO.

Br J Clin Pharmacol. 2012 Sep;74(3):477-89. doi: 10.1111/j.1365-2125.2012.04207.x.

27.

Initiating allopurinol therapy: do we need to know the patient's human leucocyte antigen status?

Lee MH, Stocker SL, Anderson J, Phillips EJ, Nolan D, Williams KM, Graham GG, Sullivan JR, Day RO.

Intern Med J. 2012 Apr;42(4):411-6. doi: 10.1111/j.1445-5994.2011.02567.x.

PMID:
21790926
28.

Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout.

Stocker SL, Graham GG, McLachlan AJ, Williams KM, Day RO.

J Rheumatol. 2011 May;38(5):904-10. doi: 10.3899/jrheum.101160. Epub 2011 Feb 1.

PMID:
21285173
29.

Lack of effect of hydrochlorothiazide and low-dose aspirin on the renal clearance of urate and oxypurinol after a single dose of allopurinol in normal volunteers.

Ng DY, Stocker SL, Graham GG, Williams KM, Day RO.

Eur J Clin Pharmacol. 2011 Jul;67(7):709-13. doi: 10.1007/s00228-010-0963-6. Epub 2010 Dec 23.

PMID:
21181139
30.

A proposal for identifying the low renal uric acid clearance phenotype.

Indraratna PL, Stocker SL, Williams KM, Graham GG, Jones G, Day RO.

Arthritis Res Ther. 2010;12(6):149. doi: 10.1186/ar3191. Epub 2010 Dec 16.

31.

Measurement of urinary oxypurinol by high performance liquid chromatography-tandem mass spectrometry.

Stocker SL, Franklin ME, Anderson JM, Pillans PI, Williams KM, McLachlan AJ, Day RO, Taylor PJ.

J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Sep 1;878(25):2363-8. doi: 10.1016/j.jchromb.2010.07.017. Epub 2010 Jul 29.

PMID:
20702150
32.

Optimizing therapy with allopurinol: factors limiting hypouricemic efficacy.

Chung Y, Stocker SL, Graham GG, Day RO.

Am J Med Sci. 2008 Mar;335(3):219-26. doi: 10.1097/MAJ.0b013e31815acb10. Review.

PMID:
18344696
33.

Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects.

Stocker SL, Williams KM, McLachlan AJ, Graham GG, Day RO.

Clin Pharmacokinet. 2008;47(2):111-8.

PMID:
18193917
34.

Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol.

Day RO, Graham GG, Hicks M, McLachlan AJ, Stocker SL, Williams KM.

Clin Pharmacokinet. 2007;46(8):623-44. Review.

PMID:
17655371
35.

When debiasing backfires: accessible content and accessibility experiences in debiasing hindsight.

Sanna LJ, Schwarz N, Stocker SL.

J Exp Psychol Learn Mem Cogn. 2002 May;28(3):497-502.

PMID:
12018501

Supplemental Content

Loading ...
Support Center